Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1
activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at
each dose level.